MedTrace Logo

MESNA for Prevention of Acute Deterioration of Renal Function Following Contrast Agent Application

NCT00223548 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 106

Last updated 2005-09-22

No results posted yet for this study

Summary

The purpose of this study is to determine wether Mesna could prevent contrast-induced nephropathy

Conditions

  • Chronic Renal Insufficiency
  • Serum Creatinine Concentration
  • Contrast Media Exposition

Interventions

DRUG

sodium 2-mercaptoethane sulfonate

Sponsors & Collaborators

  • University of Ulm

    lead OTHER

Principal Investigators

  • Frieder Keller, M.D. · Division of Nephrology, University Hospital Ulm

  • Frieder Keller, M.D. · Division of Nephrology, University Hospital of Ulm

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-10-31
Completion
2004-12-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00223548 on ClinicalTrials.gov